Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine optionsVaxart to continue leading and funding development through Phase 2b completion and End of Phase 2 meeting with…

Dyne changes plans for DM1 drug again; Dynavax licenses Vaxart's Covid vaccine

Plus, news about Cullinan, 4DMT, Axsome, AstraZeneca, Noema, UroGen Pharma, Halozyme and Benitec: ↩️ Dyne delays myotonic dystrophy plans again: Dyne said it now expects to submit an application for FDA approval of its ...

Dynavax and Vaxart Partner to Advance Oral COVID-19 Vaccine

Dynavax and Vaxart have entered into a license and collaboration agreement to advance Vaxart’s investigational oral COVID-19 vaccine, with phase 2b data expected in late 2026.